The chart displays figures for the trailing 12 months. Revenue is expected to grow by 4.0% annually for the next 3 years, exceeding the Pharmaceuticals industry in Germany. However, 2 warning signs have been identified for Dermapharm Holding, highlighting potential investment risks.